"Valuation
We value Invex Therapeutics at A$254m (A$3.38 per share) on an undiluted basis, using a risk-adjusted NPV
method to discount future cash flows through to 2035. " They are working on the basis of a 50% probability of regulatory approval and launch in US 2028 and UK/Eur in 2025. The discount rate is 12.5%
"ValuationWe value Invex Therapeutics at A$254m (A$3.38 per...
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.463M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 125000 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.8¢ | 5755 | 1 |
View Market Depth
| Last trade - 07.00am 17/10/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable